Navigation Links
PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
Date:9/15/2008

ANNAPOLIS, Md., Sept. 15 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that it has received notification from the Department of Health and Human Services (DHHS) that the Company's proposal for its recombinant protective antigen anthrax vaccine, SparVax(TM), has completed a comprehensive technical and business evaluation by DHHS and has been deemed to be technically acceptable and within the competitive range. The negotiation phase for a development and procurement contract is now underway. DHHS has stated that it intends to make an award under the solicitation by end of the year.

PharmAthene's submission was in response to a Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile (Solicitation Number: RFP BARDA 08-15) issued by DHHS on February 28, 2008, outlining a requirement to develop and procure 25 million doses of an anthrax rPA vaccine.

"We are delighted by this news and remain committed to working collaboratively with the government to develop leading, next-generation biodefense medical countermeasures to ensure our Nation's biosecurity," said David P. Wright, President and Chief Executive Officer of PharmAthene. "The issuance by DHHS of a Request for Proposals for next generation anthrax vaccines acknowledges a need for a new anthrax vaccine that offers the potential for improved safety and convenience, and we believe that our product candidate, SparVax(TM), is well positioned to meet the government's requirements."

About SparVax(TM)

SparVax(TM) is a novel second generation r
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... 2014 Kerr Corporation, a leading manufacturer of ... how-to information about dual arch impressions on its dental blog. ... Impressions,” the blog entry serves up a list of tips ... step-by-step demonstration by Dr. David Little as he crafts a ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
(Date:1/14/2014)... MO (PRWEB) January 14, 2014 Holloway ... comprehensive database of material test reports (MTRs) for all ... fabricates. Documenting test results is particularly important for equipment ... regulations. The MTR Library features search functionality that allows ...
Breaking Biology Technology:Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... and NEWTON, Mass., April 17 ,InforMedix Holdings, ... and Med-eXpert(TM) Systems to improve,medication adherence and ... prescription medication adherence solutions, announced an,agreement to ... to a broad spectrum of,Federal and State ...
... Professor,s fight against pancreatic cancer and underscores, his call-to-action for additional research ... ... of Lustgarten Foundation,s limited online book offer,as seen on ABC Primetime with Diane ... Last Lecture" were ...
... YORK, April 17 The market for congestive ... billion in 2007, and is,expected to reach $30 ... by,Kalorama Information, Congestive Heart Failure: Major World Markets, ... three factors: an,increased incidence of CHF, the application ...
Cached Biology Technology:InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions 2InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions 3InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions 4InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions 5The Lustgarten Foundation for Pancreatic Cancer Research Launches New Public Service Announcement Featuring 'Last Lecturer' Dr. Randy Pausch 2Genomics Likely to Replace Traditional Drug Therapies in Treating CHF 2
(Date:4/18/2014)... used techniques like X-ray crystallography and nuclear magnetic resonance ... structure of molecules, but such efforts have long been ... of a specific molecule and often in ordered and ... but impossible to peer into the structure of most ... soon be a thing of the past. , ...
(Date:4/18/2014)... as they,re planted may be good news for a garden. ... wild, a plant whose seeds sprouted at the first ,warm ... an insurance policy against late frosts or unexpected dry spells, ... Plants whose seeds put off sprouting until conditions are ... team of researchers working at the National Evolutionary Synthesis Center ...
(Date:4/17/2014)... clinical trials to treat tuberculosis could be the basis ... various bacteria, fungal infections and parasites, yet evade resistance, ... and collaborators. , Led by U. of I. chemistry ... the drug SQ109 attacks the tuberculosis bacterium, how the ... yeast to malaria and how targeting multiple pathways ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2Multitarget TB drug could treat other diseases, evade resistance 2
... the cells responsible for immune surveillance in the brain, ... tissue damage and infection. An international team under the ... shown that these cells may actually make a significant ... disease. About 1.2 million people are thought to suffer ...
... Washington, DC Scientists at the Lombardi Comprehensive Cancer ... five-year $7.5 million grant to tease apart in the ... protein receptor in breast cells in cancer development and treatment. ... kind of breast cancer and how she will fare during ...
... <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2010-03/asu-etb031810.php,">Chinese . TEMPE, Ariz. ... ban the export of electronics waste would likely make ... of an article from the journal Environmental Science ... call into question conventional thinking that trade bans can ...
Cached Biology News:Dangerous custodians 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 3E-waste trade ban won't end environmental threat 2
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
... The SelectFX Alexa Fluor 488 Cytochrome c ... you need to detect cytochrome c in ... c primary antibody and an Alexa ... 488 dye exhibits bright green fluorescence that ...
Kit for Detection of Mitochondrial Membrane Potential...
Biology Products: